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 Abstract. Intrinsic or acquired drug resistance poses a major
challenge to the success of chemotherapy in the clinical
management of human cancers. While acquired multidrug
resistance (MDR), whereby cells become refractory to multiple
drugs, has been extensively investigated, the mechanistic basis
for intrinsic resistance remains elusive, so that this condition
is largely unmanageable in the clinical setting. To address
this issue, we have assessed the effects of the anticancer
agent doxorubicin (DX) on a panel of human tumor cell lines
originally derived from untreated patients and tried to establish
a correlation between cell response and a number of para-
meters, including drug accumulation and/or drug efflux;
differences in expression and/or subcellular distribution of
proteins involved in the apoptotic process (e.g., p53, Bcl-2,
Bax) and intracellular signal transducers (PKC·); changes in
key detoxification processes. Based on our results, ‘classic’
multispecific drug transporters (P-glycoprotein, MDR-related
proteins) only seem to play a minor role in the intrinsically
resistant phenotype, whereas LRP may contribute to resistance
in non-small cell lung carcinoma (NSCLC) cells. No relation-
ship was observed between drug response and expression
and/or subcellular localization of apoptosis-related proteins;
however, increased PKC· levels are associated with poor
drug response, suggesting that one or more substrates of this
enzyme may be relevant to the resistant phenotype. Finally,
overactive glutathione-recycling pathways may contribute to
DX resistance.
Introduction
The resistance of human malignancies to multiple chemo-
therapeutic agents remains a major obstacle to the success
of cancer therapy. Resistance is defined as intrinsic when
previously untreated tumor cells fail to respond to one or
more anticancer agents; when tumors initially respond to anti-
cancer agents, but become refractory on subsequent treatment
cycles, the resistant phenotype is described as acquired. It
is now clear that multidrug resistance (MDR) is always
multifactorial, with at least two resistance mechanisms
simultaneously operating in the same tumor cell (1). These
may include: i) decreased drug accumulation and/or altered
intracellular distribution; ii) increased detoxification; iii)
increased DNA repair; iv) altered cell cycle regulation; and
v) uncoupling of the pathways linking cellular damage with
programmed cell death. Resistance to a number of anticancer
agents has been associated with overexpression of multi-
specific drug transporters, such as the 170 kDa P-glycoprotein
(P-gp) or members of the multidrug resistance-related protein
family (MRPs), belonging to the ATP-binding cassette (ABC)
superfamily (2-4). ABC transporters have been identified in
the plasma membrane, as well as in intracellular membranes,
whereby they might alter drug accumulation and/or access to
nuclear targets. More recently, another protein which may be
involved in drug export from the nucleus has been identified
in multidrug resistant cells and indicated as LRP (lung
resistance-related protein) (5,6). This is a 104-110 kDa protein
not belonging to the ABC superfamily, which has been
proposed to concur to nuclear pore complex formation and
to transport anticancer agents away from the nucleus (7,8).
Alternative or additional mechanisms may contribute to
the resistant phenotype, including increased activity of
detoxification systems. One such system is the glutathione
(GSH) system, which may or may not act in concert with
drug efflux pumps; changes in intracellular GSH levels
and/or in the activity of GSH-dependent enzymes (e.g., GSH
transferases and GSH reductase) have been shown to be
associated with resistance to several anticancer drugs (9).
A more general mechanism for drug resistance has
recently emerged from preclinical observations, correlating
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the efficacy of chemotherapeutic drugs with their ability to
induce apoptosis in a variety of tumor cell lines. Thus, this
mode of cell death has acquired major pharmacological
interest, raising the possibility that susceptibility to apoptosis
induction might be a critical determinant of tumor cell
response (10,11). In particular, alterations of the expression
or subcellular localization of proteins involved in the apoptotic
machinery (such as Bcl-2, Bax, p53) have been proposed to
explain the development of resistance in different cell lines.
Interestingly, post-translational modifications may also play
a significant role in determining the subcellular localization
and/or in modulating the function of resistance-related
proteins, including ABC transporters and proteins controlling
apoptosis; the · isoform of PKC has been proposed as a
major determinant for resistance-inducing post-translational
modifications (12,13).
The aim of the present study was to investigate the
molecular mechanisms associated with intrinsic resistance to
the widely used anthracycline agent doxorubicin (DX). A
panel of five human cancer cell lines from different tissues
was used, including: MCF7 breast adenocarcinoma cells,
A2780 ovarian carcinoma cells, M14 melanoma cells, A549
non-small cell lung carcinoma (NSCLC) cells; and LoVo
colon adenocarcinoma cells. All the cell lines were originally
derived from untreated patients. We evaluated: i) the response
of the cell lines to DX treatment for 120 h; ii) the relationship
between cell response, expression of drug transporters and
drug accumulation; iii) the relationship between cell response
and expression of proteins involved in apoptotic cell death,
including p53, Bcl-2, Bax; PKC· levels were also assessed
as it may act as a post-translational modulator for some of
them. Further investigations were performed in MCF7 and
A549 cells, which were the most and the least sensitive
among the cell lines tested, respectively; on these cell lines
we evaluated the effects of DX treatment on iv) intracellular
levels and subcellular distribution of p53, Bcl-2, Bax and
PKC·, and v) intracellular glutathione (GSH) levels and
glutathione transferase (GST) and glutathione reductase
(GSR) activities.
Materials and methods
Chemicals. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) and standard reagents were
purchased from Sigma-Aldrich Srl (Milan, Italy).
Cells and in vitro culture conditions. All the cell lines used in
this study were obtained from ATCC (Rockville, MD), were
cultured at 37˚C under 5% CO2 and used when in log-phase
growth. The MCF7, M14, A549 and A2780 cells were
maintained in RPMI 1640 medium supplemented with 10%
FBS, 1% antibiotic mixture and glutamine; whereas LoVo
cells were maintained in Ham's F12 medium supplemented
with 10% FBS and vitamins. All cell lines used were negative
to mycoplasms.
Cytotoxicity studies. The MTT assay (14) was used to assess
the antiproliferative effects of DX. Briefly, cells were seeded
onto 96-well plates, allowed to attach and grow for 24 h and
subsequently exposed to DX (2x10-9-2x10-6 M). After 120 h,
MTT was added for 3 h at 37˚C. Formazan crystals, formed by
mitochondrial reduction of MTT, were solubilized in DMSO
and the absorbance was read at 570 nm, using a Universal
Microplate reader EL800 (Bio-Tek Instruments).
Preparation of cell extract and subcellular fractions. Total
protein extracts were obtained by incubation of 107 cells with
60 µl of lysis buffer (1% NP40, 10 µg/ml leupeptin, 10 µg/ml
aprotinin in PBS).
To obtain subcellular fractions, 6x107 cells per sample
were washed twice in ice-cold PBS, resuspended in 2 ml
of hypotonic buffer (5 mM Tris pH 7.4, 5 mM KCl, 1.5 mM
MgCl2, 0.1 mM EGTA, 1 mM DTT) containing 0.2 mM
PMSF, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 0.7 µg/ml
pepstatin A, and incubated for 30 min on ice. After homo-
genization, samples were centrifuged at 500 x g at 4˚C to
obtain the nuclear fraction (N). The resulting supernatant was
centrifuged at 10,000 x g at 4˚C to obtain the HM fraction
(heavy membranes, mostly consisting in mitochondria) and
the supernatant from this centrifugation was then centrifuged
at 150,000 x g to obtain the LM (light membrane) and cytosolic
(C) fractions. Nuclear, HM and LM fractions were resuspended
in 0.1 ml of Triton X-100 lysis buffer (1% Triton X-100 in
PBS, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 0.2 mM PMSF).
Protein concentration in whole cell extracts and subcellular
fractions was determined by the bicinchoninic acid (BCA)
assay (Pierce, Rockford, IL, USA).
Immunoblotting. Western blot analysis was performed to
detect the levels of p53, Bax, Bcl-2 and PKC· in protein
extracts from untreated cells and the expression of the same
proteins in subcellular fractions from control and DX-treated
samples (2 µM for MCF7 cells and 50 µM for A549 cells for
24 h). 10 µg of protein per lane were loaded onto polyacryl-
amide gels (11%) and separated under denaturing conditions.
Protein bands were then transferred onto Immobilon P
membranes (Millipore, Bedford, MA, USA), and Western blot
analysis was performed by standard techniques with mouse
monoclonal antibodies (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) recognizing human Bcl-2 and p53 (DO-1),
with a rabbit anti-PKC· monoclonal antibody (Sigma-Aldrich
Srl, Milan) and with a rabbit polyclonal antibody raised
against human Bax (Pharmingen Inc., San Diego, CA, USA).
Protein bands were visualized using a peroxidase-conjugated
anti-mouse/rabbit secondary antibody and the BM Chemi-
luminescence Western blot kit (Roche, Milan, Italy).
Determination of GSH, GST and GSR levels. MCF7 and A549
control and DX-treated cells (2 µM for MCF7 cells and
50 µM for A549 cells) for 24 h were harvested with PBS-
EDTA, washed with PBS, resuspended at 107 cells/ml in
phosphate buffer and sonicated. The supernatants obtained
by centrifugation of cell sonicates at 30,000 g were used to
determine intracellular GSH levels by the fluorymetric method
described by Hissin and Hilf (15), using o-phthalaldehyde
(OPT) as a fluorescent agent. GST activity was determined
by monitoring the formation of GSH-adducts with 1-chloro-
2,4-dinitrobenzene (CDNB), according to the method described
by Habig et al (16). GSR activity was measured by the method
previously described by Colman (17).
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Flow cytometry. Flow cytometric analysis was carried out on
cell suspensions (106 cells/ml) obtained detaching monolayer
growing cells by trypsin-EDTA solution.
To evaluate the intracellular expression of P-gp and LRP
cell suspensions were fixed with 2% paraformaldehyde in PBS
and the samples were then permeabilized by adding 0.05%
Triton X-100. Incubations with the primary (MRK16, LRP-56,
LRP-42) and secondary (goat anti-mouse IgG-fluorescein
conjugate) antibodies were performed in PBS containing 1%
BSA, 10% fetal calf serum and 10% human AB serum. For
negative controls, cells were labeled with mouse isotypic
globulins.
For MRP1 detection with MAb MRPr1, cells were per-
meabilized in 10% (v/v) lysing solution G (Becton Dickinson,
Mountain View, CA) in dH2O and incubated in PBS/BSA
containing 1% normal goat serum. Cells were first incubated
with the MRPr1 antibody and subsequently with a goat anti-
rat IgG fluorescein-conjugate. For negative controls, cells
were incubated with rat isotypic globulins.
Time course studies of drug accumulation were performed
on cells treated with 2 µM DX for 1 h and 4 h. At the end of
treatments, cells were washed with ice-cold Hank's balanced
salt solution (HBSS, Sigma), detached with EDTA and trypsin,
resuspended in ice-cold PBS and immediately analyzed for
DX content. Fluorescence was analyzed with a FACScan
flow cytometer (Becton Dickinson) equipped with a 15-mW,
488 nm, air-cooled argon ion laser. Fluorescence emissions
were collected through a 530 nm band-pass filter for fluorescein
and a 575 nm band-pass filter for DX and acquired in log
mode. For DX accumulation studies, drug fluorescence
intensity was expressed as the mean fluorescence channel
(MFC) calculated from the flow cytometric profiles by the Cell
Quest software. For quantitative evaluation of P-gp, MRP
and LRP expression, protein content in arbitrary units (A.U.)
was expressed as the ratio of the MFC of labeled samples on
the MFC of negative controls.
Results
Cytotoxicity studies. Fig. 1 shows representative dose-response
curves obtained after 120 h exposure of A549, A2780, M14,
MCF7 and LoVo cells to increasing concentrations of DX.
IC50 values, determined according to the median effect equation
(18) and indicated as mean ± SE of at least 4 independent
experiments, are reported in Table I. Of all the cell lines
tested, MCF7 cells were the most sensitive to DX treatment,
followed by the colon cell line LoVo and M14 melanoma cells,
both with comparable IC50 values; A2780 ovarian carcinoma
cells exhibited a statistically significant increase in IC50 as
compared to the MCF7, LoVo and M14 cells, whereas the
NSCLC cell line A549 was significantly less responsive than
all the other cell lines tested, with approximately a 40-fold
resistance to DX treatment compared to MCF7 cells.
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Figure 1. Dose-response curves obtained for M14 (
 
), A549 (), A2780 (),
MCF7 () and LoVo () cells after 120-h continuous exposure to DX. The
curves are representative of 4-6 independent experiments; values are expressed
as the means ± SD of 6-8 determinations/experiment.
Table I. IC50 values indicated as mean ± SE of 4-6 independent
experiments.
–––––––––––––––––––––––––––––––––––––––––––––––––
Cell line IC50 ± SE (nM) p<0.05
–––––––––––––––––––––––––––––––––––––––––––––––––
M14 20.81±4.59 vs A549, A2780
A549 514.09±51.17 vs MCF7, A2780, M14, LoVo
A2780 32.47±5.75 vs MCF7, A549, M14, LoVo
MCF7 12.78±1.79 vs A549, A2780
LoVo 15.20±3.16 vs A549, A2780
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 2. DX accumulation in the five cell lines considered after 1 and 4 h of
treatment. Values are expressed as mean ± SD of 3-5 independent experiments.
DX accumulation. To verify the hypothesis that a lower
sensitivity to DX could be due to reduced intracellular drug
concentration, drug accumulation was evaluated by flow cyto-
metry at two different time points. Following cell exposure to
2 µM DX, no significant differences in DX accumulation
were observed among the cell lines considered, either after
1 h (Fig. 2A) or 4 h (Fig. 2B); therefore no significant
correlation could be established between intracellular drug
retention and cytotoxic effect.
P-gp, MRP and LRP expression. Fig. 3 shows the fluorescent
signals measured by flow cytometry (expressed in arbitrary
units), corresponding to levels of P-gp (Fig. 3A), MRP1
(Fig. 3B) and LRP (Fig. 3C) in MCF7, A549, A2780, M14
and LoVo cell lines. No significant differences in P-gp or MRP
levels were observed among the cell lines considered. In
contrast, the expression of LRP was found to be significantly
higher in A549 cells than in the other cell lines (Fig. 3C,
p<0.05 vs the other four cell lines).
Expression of the p53, Bcl-2, Bax and PKC
 
·. Fig. 4 shows
the baseline expression levels of p53 (Fig. 4A) in total cell
lysates obtained from the five cell lines considered in this
study. M14 and LoVo cells exhibited the highest p53 levels,
while MCF7 and A549 the lowest. Bax levels are highest in
A2780 cells followed by A549 and MCF7 cells and then
M14 and LoVo cell lines (Fig. 4B). Bcl-2 levels are shown on
Fig. 4C: MCF7 cells show the highest levels of expression,
followed by LoVo, A2780, M14 and A549 cell lines. The
highest PKC· protein levels were observed in A549, followed
by A2780 and M14 cells (Fig. 4D). It is possible to conclude
that no direct correlation exists between p53, Bcl-2 or Bax
protein levels and sensitivity to DX. The observation that
PKC· is undetectable in the two most sensitive cell lines
(MCF7 and LoVo), present at low and intermediate levels in
M14 and A2780 cells, respectively (which also exhibit low
and intermediate response to DX) and significantly over-
expressed in the intrinsically resistant A549 cells, suggests
a possible role for PKC· in the intrinsically resistant
phenotype.
Subcellular distribution of p53, Bcl-2, Bax and PKC·.
Western blot analysis with anti-p53 antibody showed that in
MCF7 untreated cells the protein is expressed at low levels
and mainly localized in the nuclear and mitochondrial fractions.
Exposure to DX induces an increase in p53 levels in all sub-
cellular compartments (Fig. 5A). In contrast, in A549 cells
exposed to DX translocation of p53 from the cytoplasm to
the nucleus was observed (Fig. 5B). Fig. 6A shows an increase
in Bax expression in the light membrane fraction in MCF7
cells following DX treatment, while in A549 cells Bax levels
increased in all subcellular fractions except the cytoplasm
after DX treatment (Fig. 6B).
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Figure 3. Flow cytometric analysis of P-gp, MRP and LRP levels in M14,
A549, A2780, MCF7 and LoVo cell lines. Values are expressed as mean ± SD
of 3-5 independent experiments (*p<0.05 vs the other cell lines).
Figure 4. Western blot analysis of protein extracts from untreated cells of p53
(A), Bax (B), Bcl-2 (C) and PKC· (D) in M14, A549, A2780, MCF7, and
LoVo cells.
Fig. 7A shows Bcl-2 subcellular distribution in MCF7
cells treated with DX; before treatment the protein is mainly
present in the nuclear and mitochondrial fractions; following
DX exposure, its expression increases in the cytoplasm and
decreases in the light membrane fraction, whereas nuclear
and mitochondrial expression is unmodified. In A549 cells,
Bcl-2 levels are very low or undetectable in all the subcellular
fractions examined, and DX treatment does not affect levels of
expression or subcellular distribution of the protein (Fig. 7B).
PKC· protein distribution in MCF7 cells is shown in
Fig. 8A. In this cell line a generalized increase in PKC·
protein levels can be observed in all the subcellular fractions,
including nuclei, following DX exposure. In contrast, A549
cells exhibit comparable levels of the protein in all the
subcellular fractions, except the nucleus, which exhibits
significantly lower levels; DX exposure induces an increase
in PKC· levels in the light membrane fraction and a decrease
in the cytoplasm, without affecting the nuclear levels of the
protein (Fig. 8B).
GSH, GST and GSR levels. GSH levels were measured in
MCF7 and A549 cell lines, as described in the methods section,
either with or without treatment with equitoxic doses of DX.
As reported in Fig. 9A, baseline GSH levels are higher in
MCF7 than in A549 cells. Following DX treatment, GSH
levels in MCF7 cells decreased dramatically, while the intra-
cellular GSH pool remained unaffected in A549 cells. Baseline
values of GST activity are similar in MCF7 and A549 cells
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Figure 5. p53 protein levels in subcellular fractions of MCF7 and A549 cell
lines with or without DX treatment (N, nuclear fraction; LM, light membrane
fraction; HM, heavy membrane fraction; C, cytosolic fraction).
Figure 6. Bax protein levels in subcellular fractions of MCF7 and A549 cell
lines with or without DX treatment (N, nuclear fraction; LM, light membrane
fraction; HM, heavy membrane fraction; C, cytosolic fraction).
Figure 7. Bcl-2 protein levels in subcellular fractions of MCF7 and A549 cell
lines with or without DX treatment (N, nuclear fraction; LM, light membrane
fraction; HM, heavy membrane fraction; C, cytosolic fraction).
Figure 8. PKC· protein levels in subcellular fractions of MCF7 and A549 cell
lines with or without DX treatment (N, nuclear fraction; LM, light membrane
fraction; HM, heavy membrane fraction; C, cytosolic fraction).
and a similar significant increase was evidenced in both cell
lines after DX treatment (Fig. 9B). In contrast, higher levels
of GSR activity were measured in A549 cells than in MCF7
cells, while and a minor, non-significant increase in GSR
activity was observed in both cell lines following exposure to
DX (Fig. 9C).
Discussion
The ability of tumor cells to evade the effects of anticancer
agents remains a major cause of treatment failure in cancer
patients. The term multidrug resistance (MDR) is classically
used to define a resistant phenotype whereby cells become
resistant simultaneously to different drugs with no obvious
structural resemblance and with different cellular target(s)
(1). Different pathways have been proposed to be involved
in intrinsic or acquired MDR; one of the best documented
mechanisms is modulation of intracellular drug concentrations.
This can be achieved through decrease in drug uptake or
increase in drug efflux. At present, a number of drug efflux
proteins have been characterized, including P-gp, exporting
paclitaxel, vinca alkaloids, anthracyclines and other natural
product-derived drugs (2,3), and the MRP family, with MRP1
and MRP2 also implicated in transport of anthracyclines and
vinca alkaloids (4). In the present study, we evidenced different
levels of intrinsic resistance to DX in the MCF7, A2780,
LoVo, M14 and A549 cell lines, which were selected as
representative of five different tumor types exhibiting varying
degrees of drug responsiveness in the clinic. Differences in
sensitivity did not seem to correlate with different intra-
cellular drug accumulation, as flow cytometric analysis of
this parameter did not show any significant differences among
the five cell lines tested. Determination of ABC multispecific
drug transporters did not show any significant differences
in the expression of P-gp or MRP1, suggesting that these
transporters may play minor roles in the intrinsically resistant
phenotype. In contrast, significant LRP overexpression was
detected in A549 cells, which were the most refractory to DX
treatment. This is in agreement with recent data, showing a
correlation between LRP levels and acquired resistance to
chemotherapeutic treatment in cancer cell lines (5). Recent
data from our group indicate that increased LRP expression
in A549 as compared with MCF7 cells correlates with a
different intracellular DX distribution, whereby high nuclear
drug levels can be detected in breast cells, while drug-related
fluorescence is confined to perinuclear vesicular structures in
lung cells (19). Thus, LRP overexpression seems to reduce
drug access to its molecular targets in A549 cells, even though
overall drug accumulation does not significantly differ from
that observed in the other cell lines tested; this may account for
the relative resistance of this cell line. However, the remaining
cell lines showed similar levels of this protein, even though
A2780 ovarian cells were significantly less responsive to DX
than MCF7, M14 or LoVo cells (Table I). Therefore, we can
only conclude that, while LRP may be a critical determinant
of drug resistance in lung-derived cell lines, it does not seem
to play a major role in determining the intrinsically resistant
phenotype in other cell lines.
Besides multidrug transporters, other pathways have
been involved in resistance to chemotherapeutic, including:
i) alterations of intracellular drug metabolism, either through
decreased activation or increased inactivation, ii) alterations
of cellular drug targets, such as point mutations in the DNA
topoisomerase II gene, leading to amsacrine resistance, or in the
tubulin gene, preventing paclitaxel binding, iii) enhancement
of DNA repair.
Regarding detoxification mechanisms, conjugation to
glutathione (GSH) prior to export from the cell is an important
detoxification mechanism for anticancer as well as other drugs;
furthermore, GSH has been reported to act as a cofactor for
extrusion of unconjugated agents (anthracyclines, vinca
alkaloids) by MRPs (20,21). Accordingly, MDR in tumor
cell lines is often accompanied by an increase in cellular thiol
content, in the form of GSH, and by an increase in GSH-
dependent enzymatic activities, such as glutathione transferase
and reductase (9,22,23). Comparison of GSH and GSH-
dependent enzymes in MCF7 and A549 cells indicates that
the latter are more efficient in recycling intracellular GSH by
the GSR pathway, even though GSH levels are in fact lower
than in the MCF7 cells. Efficient recycling of GSH is essential
in lung cells, which are naturally exposed to high levels
of oxygen tension and are therefore more prone to develop
oxidative stress. This property may contribute to resistance
to cytotoxic insults involving generation of oxygen-derived
reactive species (which is the case with DX). The increased
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Figure 9. GSH levels (A), GST (B) and GSR (C) activities in MCF7 and A549
cells treated with equitoxic doses of DX. Values are expressed as mean ± SD
of 4-6 independent experiments (*p<0.05 vs controls).
levels of GST observed in A549 cells after DX treatment
could also concur to the resistant phenotype, as GST levels
have frequently been related to resistance to anthracycline
anticancer agents (24,25).
More recently, the observation that effective chemo-
therapeutic drugs are able to induce apoptosis has indicated
susceptibility to apoptosis as a critical determinant of tumor
cell response to both radio- and chemotherapy (10,11).
A number of proteins able to induce or inhibit apoptosis
have been identified, including p53 and members of the Bcl-2
family of proteins (11), and changes in their expression and/or
subcellular distribution have been proposed to explain drug
resistance in different cell lines. Our results did not show any
relationship between p53, Bcl-2 and Bax protein levels and
sensitivity to DX. Changes in subcellular localization of these
proteins, which were observed in MCF7 and A549 cells, also
fail to explain the observed difference in drug responsiveness.
On the other hand, PKC· expression shows some degree of
correlation with the IC50 values obtained in our study (A549 >
A2780 > MCF7, M1, LoVo), suggesting a possible role for
PKC· in the intrinsically resistant phenotype. Different PKC
isoforms, and particularly PKC·, have been implicated in cell
resistance to cytotoxic drugs and a number of putative sub-
strates have been identified. One of the first to be examined
was P-gp, and PKC· was proposed to enhance expression
and/or function of this transporter in a number of cell lines
(26,27). However, our data seem to rule out P-gp as a relevant
substrate, as DX accumulation was similar in all cell lines
tested, in spite of different PKC· levels. Bcl-2 is another
putative candidate, as phosphorylation by PKC· has been
reported to increase its anti-apoptotic effects (28). However,
it is highly unlikely that Bcl-2 may be involved in this case,
as A549 cells only express minimal amounts of this protein,
whereas MCF7 cells exhibit high levels. In fact, A549 cells
seem to rely on another Bcl-2 family member for protection
against apoptosis, namely the Bcl-xL protein (29). A recent
report (30) indicates that bcl-x gene expression is modulated
by PKC·; therefore the relationship between PKC· and Bcl-xL
in A549 cells may be worth investigating. Finally, there is
some evidence that GST activity may also depend on PKC-
mediated phosphorylation (31).
In summary, in a small panel of human tumor cell lines we
have examined a number of putative molecular determinants
of drug response. Some of them, including classic multidrug
transporters and apoptosis-related proteins, do not seem to
affect drug response, or appear to be cell type-specific (LRP
and GSH-related enzymes). In contrast, PKC· levels increase
in parallel with drug resistance and may therefore play an
as yet undefined role in determining drug response. Further
investigations are under way to identify the relevant PKC
substrates and possible strategies to inhibit their activation.
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